A Closer Look at Allergan’s US Specialized Therapeutics
US Specialized Therapeutics segment
Allergan’s (AGN) US Specialized Therapeutics segment includes eye care products, medical aesthetics products, medical dermatology products, and neuroscience and urology products.
Interested in AGN? Don't miss the next report.
Receive e-mail alerts for new research on AGN
This segment reported revenues of $1.71 billion in 2Q17, or 15.2% higher than its $1.49 billion in 2Q16, driven by the inclusion of Zeltiq and LifeCell products as well as by the strong performance of major brands excluding Restasis and Aczone.
The eye care franchise includes products like Alphagan, Ozurdex, Restasis, and other eye care products. The eye care franchise reported revenues of ~$600 million in 2Q17—a decline of ~5.5% from its 2Q16 revenues—driven by lower sales of Restasis.
US medical aesthetics includes products for facial aesthetics, medical dermatology, a range of fillers, saline breast implants, and silicone gel under Botox brands, body contouring, and skin care products. This sub-segment reported revenues of $643.9 million in 2Q17, compared with $419.8 million in 2Q16.
Facial aesthetics products reported revenues of $349.2 million in 2Q17, while regenerative medicines including Alloderm and other products reported revenues of $115.8 million in 2Q17.
Plastic surgery, breast implants, breast reconstruction products, and other plastic surgery products reported revenues of $61.3 million in 2Q17, while body contouring products reported revenues of $78.9 million in 2Q17.
Skincare products, including Latisse brand, reported revenues of $38.7 million in 2Q17. The medical dermatology franchise, including Aczone, Botox Hyperhidrosis, Tazorac, and other advanced dermatology products, reported revenues of $81.8 million in 2Q17.
The neuroscience and urology franchise includes Botox and Rapaflo and reported revenues of $372.6 million in 2Q17.